Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

Please provide your email address to receive an email when new articles are posted on . Incidence rates for cancers included 12.88 for the exposed group and 15.04 for the unexposed group. Adjusting ...

Researchers have found in a new real-world study that dupilumab was an effective and safe therapeutic option for head and ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab is approved for atopic dermatitis in children aged 6 months and older. Patients on dupilumab did not ...

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms of moderate-to-severe atopic dermatitis (eczema) in young children whether ...

In March 2017, dupilumab (Dupixent) was approved by the FDA to treat moderate-to-severe atopic dermatitis (AD) in patients in whom topical corticosteroids either were not recommended or had failed to ...

The broadest real-life study of dupilumab in atopic dermatitis (AD) found significant improvements in adults with moderate to severe AD that were even greater than the results reported in clinical ...

The high rate of persistence found in the real-world study indicates dupilumab was well tolerated and patients were satisfied with its effectiveness. In 2017, dupilumab was approved for use in ...

The Food and Drug Administration has approved dupilumab as an add-on maintenance treatment for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not ...

Compared with dupilumab, a significantly higher proportion of patients treated with upadacitinib achieved both EASI 90 and WP-NRS 0/1 at week 16. Among patients with moderate to severe atopic ...

The number of systemic anti-inflammatory therapies for dermatologic diseases in children is expected to grow in 2026.

Dupixent is approved in 60 countries for adults with moderate-to-severe atopic dermatitis, one of the diseases driven by type 2 inflammation Atopic dermatitis is a chronic inflammatory disease that ...